-
Something wrong with this record ?
Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper
D. Farmakis, J. Alvarez, TB. Gal, D. Brito, F. Fedele, C. Fonseca, AC. Gordon, I. Gotsman, E. Grossini, F. Guarracino, VP. Harjola, Y. Hellman, L. Heunks, V. Ivancan, A. Karavidas, M. Kivikko, V. Lomivorotov, D. Longrois, J. Masip, M. Metra, A....
Language English Country Netherlands
Document type Journal Article, Review
- MeSH
- Acute Disease MeSH
- Anti-Arrhythmia Agents pharmacology therapeutic use MeSH
- Hydrazones pharmacology therapeutic use MeSH
- Cardiotonic Agents pharmacology therapeutic use MeSH
- Clinical Trials as Topic methods standards MeSH
- Humans MeSH
- Pyridazines pharmacology therapeutic use MeSH
- Heart drug effects physiology MeSH
- Heart Failure drug therapy physiopathology MeSH
- Muscle Contraction drug effects physiology MeSH
- Treatment Outcome MeSH
- Expert Testimony methods standards MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompensated heart failure (HF) patients with low cardiac output. Accumulated evidence supports several pleiotropic effects of levosimendan beyond inotropy, the heart and decompensated HF. Those effects are not readily explained by cardiac function enhancement and seem to be related to additional properties of the drug such as anti-inflammatory, anti-oxidative and anti-apoptotic ones. Mechanistic and proof-of-concept studies are still required to clarify the underlying mechanisms involved, while properly designed clinical trials are warranted to translate preclinical or early-phase clinical data into more robust clinical evidence. The present position paper, derived by a panel of 35 experts in the field of cardiology, cardiac anesthesiology, intensive care medicine, cardiac physiology, and cardiovascular pharmacology from 22 European countries, compiles the existing evidence on the pleiotropic effects of levosimendan, identifies potential novel areas of clinical application and defines the corresponding gaps in evidence and the required research efforts to address those gaps.
Cardiology Clinic Heart Institute Hadassah University Hospital Jerusalem Israel
Cardiology Clinic Rabin Medical Center Petah Tikva Israel
Cardiology Clinic University and Civil Hospital Brescia Italy
Cardiology Department Centro Hospitalar Lisboa Norte Hospital de Santa Maria Lisbon Portugal
Critical Care Proprietary Products Orion Pharma Espoo Finland
Department Cardiothoracic Anaesthesia Heart Centre Rigshospitalet Copenhagen Denmark
Department Of Cardiology Cumhuriyet University Sivas Turkey
Department of Cardiology G Gennimatas General Hospital Athens Greece
Department of Cardiology Sismanoglio and Amalia Fleming General Hospital Athens Greece
Department of Cardiology University Clinical Centre Ljubljana Ljubljana Slovenia
Department of Cardiovascular Sciences University of Leuven Leuven Belgium
Department of Intensive Cardiac Therapy Medical University Łodz Poland
Department of Intensive Care Radboud University Medical Center Nijmegen The Netherlands
Emergency Cardiology Department University Hospital Center Zagreb Croatia
Emergency Medicine Helsinki University Helsinki University Hospital Helsinki Finland
Heart Failure Service Carmel Medical Center Haifa Israel
Innere Medizin 3 Universitätsklinik Innsbruck Innsbruck Austria
Intensive Care Unit Hospital de Sant Joan Despí Moisès Broggi Sant Joan Despí Barcelona Spain
Laboratory of Physiology University East Piedmont Novara Italy
Medizinische Klinik 2 Klinikum Weiden Weiden Germany
Section of Anaesthetics Pain Medicine and Intensive Care Imperial College London London UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18017112
- 003
- CZ-PrNML
- 005
- 20230131101822.0
- 007
- ta
- 008
- 180515s2016 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijcard.2016.07.202 $2 doi
- 035 __
- $a (PubMed)27498374
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Farmakis, Dimitrios $u Heart Failure Unit, Department of Cardiology, National and Kapodistrian University of Athens, Athens University Hospital Attikon, Athens, Greece. Electronic address: dimitrios_farmakis@yahoo.com. $7 xx0281405
- 245 10
- $a Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper / $c D. Farmakis, J. Alvarez, TB. Gal, D. Brito, F. Fedele, C. Fonseca, AC. Gordon, I. Gotsman, E. Grossini, F. Guarracino, VP. Harjola, Y. Hellman, L. Heunks, V. Ivancan, A. Karavidas, M. Kivikko, V. Lomivorotov, D. Longrois, J. Masip, M. Metra, A. Morelli, M. Nikolaou, Z. Papp, A. Parkhomenko, G. Poelzl, P. Pollesello, HB. Ravn, S. Rex, H. Riha, SE. Ricksten, RHG. Schwinger, B. Vrtovec, MB. Yilmaz, M. Zielinska, J. Parissis,
- 520 9_
- $a Levosimendan is a positive inotrope with vasodilating properties (inodilator) indicated for decompensated heart failure (HF) patients with low cardiac output. Accumulated evidence supports several pleiotropic effects of levosimendan beyond inotropy, the heart and decompensated HF. Those effects are not readily explained by cardiac function enhancement and seem to be related to additional properties of the drug such as anti-inflammatory, anti-oxidative and anti-apoptotic ones. Mechanistic and proof-of-concept studies are still required to clarify the underlying mechanisms involved, while properly designed clinical trials are warranted to translate preclinical or early-phase clinical data into more robust clinical evidence. The present position paper, derived by a panel of 35 experts in the field of cardiology, cardiac anesthesiology, intensive care medicine, cardiac physiology, and cardiovascular pharmacology from 22 European countries, compiles the existing evidence on the pleiotropic effects of levosimendan, identifies potential novel areas of clinical application and defines the corresponding gaps in evidence and the required research efforts to address those gaps.
- 650 _2
- $a akutní nemoc $7 D000208
- 650 _2
- $a antiarytmika $x farmakologie $x terapeutické užití $7 D000889
- 650 _2
- $a kardiotonika $x farmakologie $x terapeutické užití $7 D002316
- 650 _2
- $a klinické zkoušky jako téma $x metody $x normy $7 D002986
- 650 _2
- $a znalecký posudek $x metody $x normy $7 D005104
- 650 _2
- $a srdce $x účinky léků $x fyziologie $7 D006321
- 650 _2
- $a srdeční selhání $x farmakoterapie $x patofyziologie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydrazony $x farmakologie $x terapeutické užití $7 D006835
- 650 _2
- $a svalová kontrakce $x účinky léků $x fyziologie $7 D009119
- 650 _2
- $a pyridaziny $x farmakologie $x terapeutické užití $7 D011724
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Alvarez, Julian $u Department of Anesthesia and Surgical ICU, University of Santiago de Compostela, Santiago de Compostela, Spain.
- 700 1_
- $a Gal, Tuvia Ben $u Cardiology Clinic Rabin Medical Center, Petah Tikva, Israel.
- 700 1_
- $a Brito, Dulce $u Cardiology Department Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisbon, Portugal.
- 700 1_
- $a Fedele, Francesco $u Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, Sapienza University of Rome, Rome, Italy.
- 700 1_
- $a Fonseca, Candida $u Heart Failure Unit, Department of Internal Medicine, Hospital São Francico Xavier, Centro Hospitalar Lisboa Ocidental, NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.
- 700 1_
- $a Gordon, Anthony C $u Section of Anaesthetics, Pain Medicine and Intensive Care, Imperial College London, London, UK.
- 700 1_
- $a Gotsman, Israel $u Cardiology Clinic, Heart Institute, Hadassah University Hospital Jerusalem, Israel.
- 700 1_
- $a Grossini, Elena $u Laboratory of Physiology, University East Piedmont, Novara, Italy.
- 700 1_
- $a Guarracino, Fabio $u Department of Anaesthesia and Critical Care Medicine, Cardiothoracic Anaesthesia and Intensive Care, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
- 700 1_
- $a Harjola, Veli-Pekka $u Emergency Medicine, Helsinki University, Helsinki University Hospital, Helsinki, Finland.
- 700 1_
- $a Hellman, Yaron $u Heart Failure Service, Carmel Medical Center, Haifa, Israel.
- 700 1_
- $a Heunks, Leo $u Department of Intensive Care, Radboud University Medical Center, Nijmegen, The Netherlands.
- 700 1_
- $a Ivancan, Visnja $u Emergency Cardiology Department, University Hospital Center, Zagreb, Croatia.
- 700 1_
- $a Karavidas, Apostolos $u Department of Cardiology, G. Gennimatas General Hospital, Athens, Greece.
- 700 1_
- $a Kivikko, Matti $u Critical Care Proprietary Products, Orion Pharma, Espoo, Finland.
- 700 1_
- $a Lomivorotov, Vladimir $u Department of Anesthesiology and Intensive Care, State Research Institute of Circulation Pathology, Novosibirsk, Russia.
- 700 1_
- $a Longrois, Dan $u Département d'Anesthésie Réanimation Chirurgicale, Hôpital Bichat-Claude Bernard, Université Paris-Diderot, Hôpitaux Uiversitaires Paris Nord Val de Seine, Paris, France.
- 700 1_
- $a Masip, Josep $u Intensive Care Unit, Hospital de Sant Joan Despí Moisès Broggi, Sant Joan Despí, Barcelona, Spain.
- 700 1_
- $a Metra, Marco $u Cardiology Clinic, University and Civil Hospital, Brescia, Italy.
- 700 1_
- $a Morelli, Andrea $u Department of Anesthesiology and Intensive Care, Policlinico "Umberto I" University of Rome "La Sapienza", Rome, Italy.
- 700 1_
- $a Nikolaou, Maria $u Department of Cardiology, Sismanoglio and Amalia Fleming General Hospital, Athens, Greece.
- 700 1_
- $a Papp, Zoltán $u Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
- 700 1_
- $a Parkhomenko, Alexander $u Department of Anesthesiology and Intensive Care Unit for Cardiac Surgery Patients, Institute of Cardiology, Kiev, Ukraine.
- 700 1_
- $a Poelzl, Gerhard $u Innere Medizin III, Universitätsklinik Innsbruck, , Innsbruck, Austria.
- 700 1_
- $a Pollesello, Piero $u Critical Care Proprietary Products, Orion Pharma, Espoo, Finland.
- 700 1_
- $a Ravn, Hanne Berg $u Department Cardiothoracic Anaesthesia, Heart Centre, Rigshospitalet, Copenhagen, , Denmark.
- 700 1_
- $a Rex, Steffen $u Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
- 700 1_
- $a Riha, Hynek $u Cardiothoracic Anaesthesiology and Intensive Care, Department of Anaesthesiology and Intensive Care Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Ricksten, Sven-Erik $u Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden.
- 700 1_
- $a Schwinger, Robert H G $u Medizinische Klinik II, Klinikum Weiden, Weiden, Germany.
- 700 1_
- $a Vrtovec, Bojan $u Department of Cardiology, University Clinical Centre Ljubljana, Ljubljana, Slovenia.
- 700 1_
- $a Yilmaz, M Birhan $u Department Of Cardiology, Cumhuriyet University, Sivas, Turkey.
- 700 1_
- $a Zielinska, Marzenna $u Department of Intensive Cardiac Therapy, Medical University, Łodz, Poland.
- 700 1_
- $a Parissis, John $u Heart Failure Unit, Department of Cardiology, National and Kapodistrian University of Athens, Athens University Hospital Attikon, Athens, Greece.
- 773 0_
- $w MED00002299 $t International journal of cardiology $x 1874-1754 $g Roč. 222, č. - (2016), s. 303-312
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27498374 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180515 $b ABA008
- 991 __
- $a 20230131101818 $b ABA008
- 999 __
- $a ok $b bmc $g 1300736 $s 1013952
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 222 $c - $d 303-312 $e 20160729 $i 1874-1754 $m International journal of cardiology $n Int J Cardiol $x MED00002299
- LZP __
- $a Pubmed-20180515
